|3.||Breast Neoplasms (Breast Cancer)
|4.||Neoplasm Metastasis (Metastasis)
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Walker, Bruce D: 23 articles (12/2014 - 09/2002)|
|2.||Shariat, Shahrokh F: 22 articles (12/2013 - 02/2002)|
|3.||Zhang, Li: 21 articles (09/2015 - 08/2005)|
|4.||Small, Eric J: 21 articles (06/2015 - 08/2002)|
|5.||Shang, Hong: 19 articles (06/2015 - 01/2004)|
|6.||Van Cutsem, Eric: 19 articles (05/2015 - 01/2004)|
|7.||Fawzi, Wafaie W: 19 articles (01/2015 - 06/2002)|
|8.||Nakagawa, Kazuhiko: 18 articles (08/2015 - 12/2008)|
|9.||Remuzzi, Giuseppe: 18 articles (07/2015 - 05/2002)|
|10.||Socinski, Mark A: 17 articles (07/2015 - 09/2002)|
|1.||Biological Markers (Surrogate Marker)IBA
01/01/2009 - "In view of such significant correlations, we conclude that these specific microvascular abnormalities can serve as unique physiologic markers of endothelial dysfunction to correlate with the biochemical markers of inflammatory/endothelial dysfunction in disease progression and therapeutic efficacy studies."
01/01/2014 - "Nevertheless, the realization that all of these efforts seek to pursue an effective treatment and cure for the disease has spurred a significant interest in the development of promising biomarkers of cell death to early diagnose disease and accurately predict disease progression and outcome. "
04/19/2013 - "Nevertheless, urinary metabolites have not been extensively explored as a source of biomarkers for MS. We demonstrate that urinary metabolites have significant promise for monitoring disease-progression, and response to treatment in MS patients. "
01/01/2013 - "Good biomarkers for PD could be helpful for early diagnosis, management and tracking of disease progression. "
07/01/2012 - "Also we found that SD-OCT is superior to TD-OCT for detecting anterior visual pathway damage in MS. This makes both color-visual measures and SD-OCT strong candidate biomarkers of disease progression."
|2.||trastuzumab (Herceptin)FDA Link
10/01/2012 - "The efficacy of trastuzumab beyond metastatic disease progression has been confirmed by prospective randomized clinical trials, and other drugs may have the same properties. "
11/01/2013 - "The administration of trastuzumab therapy after disease progression may contribute to improved treatment outcomes. "
11/01/2012 - "The efficacy of trastuzumab beyond metastatic disease progression (PD) is controversial. "
11/01/2013 - "In HER2-positive disease, the data from observational and retrospective studies support a clinical benefit from the use of trastuzumab beyond disease progression and emerging evidences from randomized controlled trials are leading to the introduction of newer HER2-targeted therapies in multiple lines. "
02/01/2012 - "In general, data from retrospective and observational studies suggest that there may be clinical benefit when trastuzumab is used beyond disease progression. "
05/07/2012 - "A subgroup analysis of ICON7 suggested that bevacizumab therapy may also be beneficial in patients at high risk of disease progression. "
12/01/2015 - "The results of the present study demonstrated that ITGB1 inhibition effectively reduced tumorigenesis and disease exacerbation, and contributed to bevacizumab anticancer therapy via the FAK/STAT1 signaling pathway, suggesting that inhibition of ITGB1 is a potential novel therapeutic strategy for ovarian carcinogenesis. "
09/01/2012 - "In a phase II study, 62 patients with recurrent/persistent EOC/PPC were treated with bevacizumab (15 mg/kg IV q21 days) until disease progression. "
01/01/2012 - "However, there have been no evidence-based studies to support the continued use of bevacizumab beyond disease progression in such patients treated with the drug in first-line therapy. "
01/01/2011 - "This retrospective analysis of five placebo-controlled clinical trials does not support a decreased time to disease progression, increased mortality, or altered disease progression pattern after cessation of bevacizumab therapy."
02/01/1999 - "Six of 31 assessable patients (19%) responded favorably to gemcitabine, 11 patients (35%) displayed no change, and 14 patients (45%) had disease progression. "
12/01/2004 - "Randomized phase III trials with gemcitabine have yielded response rates that have translated into time to disease progression and survival benefits. "
09/15/2015 - "Gemcitabine was given on a weekly basis, following the siG12D-LODERTM insertion, until disease progression. "
04/01/2015 - "BTC patients were treated with 21-day cycles of HAI of gemcitabine (1000 mg/m(2) on days 1 and 8) and oral S-1 (60, 70, or 80 mg/m(2) on days 1-14) until disease progression occurred. "
10/01/2014 - "Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression. "
|5.||Paclitaxel (Taxol)FDA LinkGeneric
07/05/2000 - "The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL."
12/01/2011 - "Twenty-five patients were enrolled in a single-arm phase 2 multicentre study and treated with 175 mg/m² paclitaxel at 3-wk intervals until disease progression or irreversible toxicity. "
08/01/1997 - "In the first 20 evaluable patients accrued (cohort A), myelosuppression was tolerable, but cumulative peripheral sensory neuropathy proved dose limiting: grade > or = 1 in 15 (75%) patients and grade 3 in six (30%), generally occurring at paclitaxel doses > or = 215 mg/m2 and obligating at least three patients to be removed from study despite absence of disease progression. "
12/01/1996 - "Cumulative peripheral sensory neuropathy grade > or = 1 in 15 (75%) patients and grade 3 in six (30%), however, generally occurring at paclitaxel doses greater than 215 mg/m2, obligated removal from study of at least three patients, despite the absence of disease progression, and proved to be dose-limiting. "
04/01/2015 - "Upon disease progression, patients could continue, at the investigator's discretion, afatinib (40mg) with the addition of paclitaxel (80mg/m(2) weekly for 3 weeks/4-week cycle). "
|6.||docetaxel (Taxotere)FDA Link
01/01/2011 - "Between November 2005 and January 2009, 45 patients initially responding to docetaxel and then experiencing disease progression after a period of biochemical remission of at least 5 months were enrolled in a prospective multicenter study and re-treated with docetaxel. "
06/01/2008 - "All patients had been treated with docetaxel and had disease progression within 6 months after completion of first-line treatment. "
02/01/2009 - "This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression. "
03/01/2000 - "Twenty-nine women were enrolled onto a study of weekly docetaxel given at 40 mg/m(2)/wk. Each cycle consisted of 6 weeks of therapy followed by a 2-week treatment break, repeated until disease progression or removal from study for toxicity or patient preference. "
12/01/2015 - "All had mCRPC with disease progression during or after docetaxel. "
01/01/2014 - "Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. "
09/15/2009 - "Patients with UC were eligible if they received a prior platinum-based regimen in the neoadjuvant/adjuvant setting or as first-line treatment for advanced/metastatic disease and had developed disease progression within 12 months. "
01/01/2015 - "The results from the current study, for the first time to our knowledge, provide suggestive evidence of an effect of TERT polymorphisms on disease progression variability among Chinese patients with platinum-treated advanced NSCLC."
04/20/2009 - "The aim of this study is to compare the toxic effects, disease progression time and overall survival time between advanced NSCLC patients 60 or older than 60 and younger than 60 who are administrated with palitaxel plus platinum-based agents. "
02/01/2009 - "Two trials have investigated the timing of a second-line therapy after completion of four cycles of platinum-based therapy versus the standard treatment paradigm of initiating second-line therapy upon disease progression. "
|8.||Cisplatin (Platino)FDA LinkGeneric
01/01/1987 - "These findings provide reasons to study both treatment with cisplatin before disease progression reduces the number of favorable characteristics and systematic second attempts at debulking surgery."
07/01/2004 - "In the other 4 dogs cisplatin was not administered as prescribed because the dogs were withdrawn from treatment due to disease progression or radiation effects. "
05/01/2001 - "Patients who do poorly despite ABMT have a mediastinal primary site, true cisplatin-refractory disease, disease progression prior to ABMT, and/or markedly elevated betaHCG at ABMT. "
02/01/2000 - "Cisplatin was given at a dose of 60 mg/m(2) once every 4 weeks, and treatment was continued for up to 12 weeks if no disease progression occurred. "
09/15/1993 - "Among the 24 MNSGCT, 10 were treated before 1980 without cisplatin and all but 1 died of disease progression. "
|9.||imatinib (Gleevec)FDA Link
01/01/2006 - "While imatinib is highly effective therapy, with improving prospects over time for sustained remission and potential to severely limit or eliminate disease progression and transformation, a minority of patients either fail or respond suboptimally to imatinib; as well, disease eradication may not be possible with imatinib. "
01/01/2008 - "This report supports the view that imatinib is a safe and effective drug in controlling disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life."
03/01/2003 - "Based on this relatively small series of patients, we conclude that acquisition of clonal evolution increases the risk of subsequent disease progression also in CML patients in complete hematologic remission on imatinib."
03/01/2003 - "Therefore, to investigate whether CE as an isolated event increases the risk of disease progression during imatinib treatment, we compared the outcome of patients with CML in chronic phase (CML-CP) who developed CE whilst in complete hematologic remission with the outcome of comparable patients in complete hematologic remission who showed no evidence of CE. "
01/01/2013 - "Here, we tried to identify potential drug resistance mechanisms against imatinib in a 46-year old female with DFSP who initially responded well to imatinib but suffered rapid disease progression. "
02/20/2004 - "The known structure of the fragments permits the generation of neo-epitope antibodies to the cleavage site, which can be used to detect ongoing cartilage degradation in patients with arthritic disease, an important adjunct in monitoring disease progression, active disease, and efficacy of treatment."
04/01/1999 - "Strong antibody responses are often seen in human immunodeficiency virus type 1 (HIV-1) carriers, but it is not known whether these antibodies are effective in the inhibition of disease progression. "
02/01/1989 - "These results argue against a role for antibodies to this LAV-1/HTLV-IIIB neutralization domain in protection against disease progression."
01/14/2015 - "Several observational studies support a role for ADCC antibodies in slowing HIV disease progression. "
07/01/2013 - "However, vaccine studies and studies of spontaneous controllers are finally providing correlates of immunity from protection and disease progression, including virus-specific CD4(+) T-cell responses, binding anti-bodies, innate immune responses, and generation of antibodies with potent antibody-dependent cell-mediated cytotoxicity activity. "
|1.||Drug Therapy (Chemotherapy)
05/01/1992 - "Given this response rate to radiation therapy and the difficulty of dissection and associated morbidity with the surgical excision of postchemotherapy residual masses, the best option at this time may be observation with salvage chemotherapy and/or radiation reserved for those with disease progression."
05/01/2015 - "These interactions have important clinical implications for chemotherapy because ultimately they determine therapeutic efficacy, disease progression/relapse and the success or failure of patient treatment."
05/01/2012 - "At the 1-year follow-up visits, PVP combined with chemotherapy achieved complete remission (CR) in six patients (15.8%); near complete remission (nCR) in ten patients (26.30%); partial remission (PR) in nine patients (23.7%); minimal response (MR) in three patients (7.9%); no change (NC) in four patients (10.5%), and disease progression (DP) in five patients (13.2%). "
01/01/2012 - "Patients were divided into two groups: a group resistant to chemotherapy (9 patients--disease progression, stable disease) and a group with positive clinical response (9 patients--complete and partial remission). "
07/01/2009 - "Following chemotherapy, we noticed a progressive increase in lipid levels in NHL patients with complete remission (CR) and stable disease (SD), and further decrease in patients with the disease progression. "
03/01/1997 - "Application of androgen suppression as an adjuvant to definitive radiotherapy has been associated with a highly significant improvement in local control and freedom from disease progression. "
06/01/2014 - "Only radiotherapy (XRT) has proven to be effective in delaying the disease progression. "
07/01/2004 - "On the first follow-up examination (2 months after the end of radiotherapy) 65.9% of the patients were in complete remission (CR), 31.7% in partial remission (PR), while in one (2.4%) patient locoregional disease progression (PD) was registered. "
12/01/1996 - "Analysis of the recurrence and survival rates demonstrated that radiotherapy did not confer any significant protection against recurrence or disease progression. "
01/01/2015 - "This study found that early postoperative radiotherapy is associated with an increase in time to progression compared to observation (and delayed radiotherapy upon disease progression) for people with LGG but does not significantly improve overall survival (OS). "
08/01/1992 - "At the present time, data remain limited, but three controlled studies have found statistically significant reductions in the rate of disease progression, and one has found a significant reduction in the mortality rate, with BCG immunotherapy. "
03/01/1999 - "Four out of twelve patients achieved complete remission (CR), one patient had a partial remission (PR), three were stable and four had disease progression under radio therapy and chemo-immunotherapy. "
01/01/1995 - "In contrast, intravesical bacillus Calmette-Guérin (BCG) immunotherapy is effective in high-grade tumours, provides long-term protection from tumour recurrence and reduces disease progression. "
10/01/2012 - "Immunotherapy is the only etiology-based treatment that has the potential for disease modification, as reflected by longterm remission following its discontinuation and possibly prevention of disease progression and onset of new allergic sensitizations. "
01/01/2014 - "Along with understanding of the immune basis came an appreciation that immunotherapy modifies allergic disease expression, producing protection against disease progression and symptomatic improvement that persists for years after the treatment is discontinued. "
|4.||Highly Active Antiretroviral Therapy (HAART)
08/01/2004 - "Monitoring the efficacy of highly active antiretroviral treatment (HAART) is crucial if disease progression and the emergence of viral mutants are to be avoided. "
07/01/2001 - "Highly active antiretroviral therapy (HAART) has been shown to be highly effective in controlling HIV-related disease progression. "
06/01/2007 - "The understanding of viral pathogenesis, the development of highly active antiretroviral therapy, and the ability to quantitate viral burden have led to significant reduction in disease progression and morbidity in HIV-infected children. "
06/01/2006 - "HAART use in pregnancy provides significant benefits in delaying HIV disease progression and reducing the risk of mother-to-child-transmission, but may be counterproductive in terms of successful pregnancy outcome."
11/23/2001 - "Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 x 10(6) CD4 lymphocytes/l is effective in slowing disease progression."
01/01/2013 - "Placement of a graft for a moderate lesion was associated with significantly greater incidence of disease progression, most marked in the right coronary territory. "
12/27/1996 - "Early complete hemodynamic evaluation before the onset of severe symptoms, followed by serial evaluations of disease progression and consultation with a transplant center, should result in earlier, more appropriate time of listing and improved survival. "
02/01/2001 - "The use of this immunoablative conditioning regimen in auto-HSCT transplant was shown to be effective in controlling disease progression and could be a valuable strategy in reducing TRM."
06/01/2015 - "We identified 42 patients with MCL who discontinued therapy due to disease progression on treatment (n = 28), toxicity (n = 6), elective stem-cell transplant in remission (n = 4) or withdrawn consent (n = 4). "
07/01/2013 - "With regard to disease progression, it was detected that two cases (of whom one was renal and one was bone marrow transplant patient) lost their lives (mortality rate: 14%), however all the other cases were cured completely. "